NASDAQ:XFOR
X4 Pharmaceuticals Inc. Stock News
$0.91
+0.0085 (+0.95%)
At Close: May 22, 2024
X4 Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference
08:00am, Wednesday, 07'th Apr 2021
BOSTON, April 07, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CX
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 01'st Apr 2021
BOSTON, April 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CX
X4 Pharmaceuticals Announces $55.0 Million At-the-Market Private Placement Financing
08:01am, Friday, 19'th Mar 2021
BOSTON, March 19, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CX
X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q4 2020 Results - Earnings Call Transcript
01:20pm, Thursday, 04'th Mar 2021
X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q4 2020 Results - Earnings Call Transcript
X4 Pharmaceuticals to Participate at the Virtual B. Riley Oncology Institutional Investor Conference
08:00am, Tuesday, 19'th Jan 2021
BOSTON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXC
X4 Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect Conference
08:00am, Thursday, 07'th Jan 2021
BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXC
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Monday, 04'th Jan 2021
BOSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXC
X4 Pharmaceuticals (XFOR) Surges: Stock Moves 6.9% Higher
12:02pm, Friday, 18'th Dec 2020
X4 Pharmaceuticals (XFOR) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
X4 Pharmaceuticals Appoints Diego Cadavid, M.D., as Chief Medical Officer
08:00am, Monday, 14'th Dec 2020
BOSTON, Dec. 14, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXC
X4 Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Mavorixafor for the Treatment of WHIM Syndrome
08:00am, Thursday, 10'th Dec 2020
BOSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXC
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 01'st Dec 2020
BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXC
X4 Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference
08:00am, Tuesday, 10'th Nov 2020
BOSTON, Nov. 10, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXC
X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q3 2020 Results - Earnings Call Transcript
02:49pm, Saturday, 07'th Nov 2020
X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q3 2020 Results - Earnings Call Transcript
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Monday, 02'nd Nov 2020
BOSTON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXC
X4 Pharmaceuticals Appoints Art Taveras, Ph.D., as Chief Scientific Officer
08:00am, Monday, 02'nd Nov 2020
CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction
